![Identification of Functional MKK3/6 and MEK1/2 Homologs from Echinococcus granulosus and Investigation of Protoscolecidal Activity of Mitogen-Activated Protein Kinase Signaling Pathway Inhibitors <i>In Vitro</i> and <i>In Vivo</i>. - Abstract - Europe PMC Identification of Functional MKK3/6 and MEK1/2 Homologs from Echinococcus granulosus and Investigation of Protoscolecidal Activity of Mitogen-Activated Protein Kinase Signaling Pathway Inhibitors <i>In Vitro</i> and <i>In Vivo</i>. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6325220/bin/AAC.01043-18-f0005.jpg)
Identification of Functional MKK3/6 and MEK1/2 Homologs from Echinococcus granulosus and Investigation of Protoscolecidal Activity of Mitogen-Activated Protein Kinase Signaling Pathway Inhibitors <i>In Vitro</i> and <i>In Vivo</i>. - Abstract - Europe PMC
![PDF) In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer PDF) In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer](https://www.researchgate.net/publication/303535657/figure/fig1/AS:365993659518977@1464271096497/llustration-of-sorafenib-loaded-nanomedicines_Q320.jpg)
PDF) In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer
![PDF) Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma PDF) Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma](https://i1.rgstatic.net/publication/5895054_Phase_II_Study_to_Investigate_the_Efficacy_Safety_and_Pharmacokinetics_of_Sorafenib_in_Japanese_Patients_with_Advanced_Renal_Cell_Carcinoma/links/53d5a0a20cf228d363ea0d95/largepreview.png)
PDF) Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma
Aan de Minister van Volksgezondheid, Welzijn en Sport Postbus 20350 2500 EJ 'S-GRAVENHAGE 3 augustus 2006 Farmatec/P-2705783 2
![Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase | SpringerLink Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00894-015-2708-z/MediaObjects/894_2015_2708_Fig2_HTML.gif)
Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase | SpringerLink
![PDF) SP94-Targeted Nanoparticles Enhance the Efficacy of Sorafenib and Improve Liver Cancer Cell Discrimination PDF) SP94-Targeted Nanoparticles Enhance the Efficacy of Sorafenib and Improve Liver Cancer Cell Discrimination](https://www.researchgate.net/profile/Cameron-Evans-3/publication/348093444/figure/fig2/AS:1101118306287617@1639538470547/Cell-viability-assay-of-A-Hep3B-treated-with-sorafenib-control-sorafenib-NPs_Q320.jpg)